AstraZeneca PLC’s Plavix Rival Brilique Wins EU Approval

LONDON, Dec 6 (Reuters) - AstraZeneca's (AZN.L) new heart medicine Brilique -- or Brilinta -- won final clearance from EU regulators on Monday, putting it on track to compete with Plavix, the world's second biggest-selling drug, next year.